Compare Charter Communications Inc (CHTR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs Viatris Inc — how do they compare? Charter Communications Inc trades at $131.33 (market cap $15.73B), while Viatris Inc trades at $16.6 (market cap $18.99B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.94% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| CHTR | VTRS | |
|---|---|---|
Market Cap | $15.73B | $18.99B |
Sector | Media | Health |
52-Week High | $398.11 | $17.39 |
52-Week Low | $125.54 | $8.74 |
Enterprise Value | $112.04B | $31.20B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charter Communications (CHTR) trades at $131.37, up 0.49% today, amid mixed technical signals with a bearish moving average trend but bullish oscillators. The stock appears deeply undervalued with a P/E of 3.55 and EV/EBITDA of 5.3, supported by a 9.03% net income margin and strong cash flow. Recent news highlights potential strategic partnerships with SpaceX and acquisition interest from Comcast, driving investor optimism despite recent earnings misses.
The outlook for CHTR is cautiously optimistic, with significant upside potential based on analyst consensus targets near $196.20. Key opportunities include valuation discount, cash flow inflection, and strategic moves, while risks involve high debt levels, competitive pressures, and execution on subscriber growth. The stock's current level near support at $130 suggests a critical juncture for near-term direction.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
